Role of biomarkers in risk stratification of acute coronary syndrome

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 627-633

  Nagesh, C M ^a   Roy, Ambuj ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute coronary syndrome; Brain natriuretic peptide; Cardiac biomarkers; CRP; Cystatin C; Troponin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CYSTATIN C; FATTY ACID BINDING PROTEIN; ISCHEMIA MODIFIED ALBUMIN; METALLOPROTEINASE; MYELOPEROXIDASE; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN; TROPONIN I; TROPONIN T; DIAGNOSTIC AGENT;

ACUTE CORONARY SYNDROME; ASSAY; CORONARY ARTERY DISEASE; CORONARY RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEART FAILURE; HEART MUSCLE NECROSIS; INFLAMMATION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LABORATORY TEST; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; HUMAN; METHODOLOGY; PERSONALIZED MEDICINE;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; HUMANS; INDIVIDUALIZED MEDICINE; NATRIURETIC PEPTIDE, BRAIN; RISK ASSESSMENT; TROPONIN;

EID: 78649473391     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000; 35: 449-61.
2. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
3. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
4. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333-41.
5. Galvani M, Ottani F, Ferrini D, Ladenson JH, Destro A, Baccos D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997; 95: 2053-9.
6. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50: 327-32.
7. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It's time for a change to a troponin standard. Circulation 2000; 102: 1216-20.
8. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106: 202-7.
9. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286: 2405-12.
10. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponin in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002; 40: 2065-71.
11. De Zoysa JR. Cardiac troponins and renal disease. Nephrology (Carlton) 2004; 9: 83-8.
12. Ooi DS, Isotalo PA, Veinot JP. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin Chem 2000; 46: 338-44.
13. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002; 346: 2047-52.
14. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337: 1648-53.
15. Higgins JP, Higgins JA. Elevation of cardiac troponin I indicates more than myocardial ischemia. Clin Invest Med 2003; 26: 133-47.
16. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Dalluge J, et al. Standardization of cardiac troponin I assays: round robin of ten candidate reference materials. Clin Chem 2001; 47: 431-7.
17. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
18. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-8.
19. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes incirculating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44: 1988-95.
20. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphpy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3.
21. Suleiman M, Aronson D, Reisner SA, Kapelovich MR, Morkiewics W, Levy Y, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003; 115: 695-701.
22. Suleiman M, Khatib, R, Agmon Y, Mehamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47: 962-8.
23. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimora JR, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998; 82: 715-9.
24. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460-5.
25. Bogaty P, Boyer L, Simard S, Danwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51: 2339-46.
26. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
27. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tale J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24.
28. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102-11.
29. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003; 197: 615-24.
30. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Mungel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-5.
31. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
32. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-103.
33. Szmitko PE, Wang C-H, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation. Part 1. Circulation 2003; 108:1917-23.
34. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
35. Heeschen C, Dimmeler S, Hamm CW, Van den Brond MJ, Boersma E, zeiher AM. et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-11.
36. Kinlay, S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110: 386-91.
37. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rafai N, Braunwald E, et al. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 2007; 26: 79-84.
38. Consuegra-Sanchez L, Bouzas-Mosquera A, Sinha MK, Collinson PO, Gaze DC, Kaski JC. Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 2008; 23: 174-80.
39. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004; 35: 1-5.
40. Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs 2003; 35: 36-8, 40.
41. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345:1022-9.
42. Heeschen C, Dimmeler S, Hamm CW, Fichtscherer S, Simoons ML, Zeiher AM, CAPTURE Study Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005; 45: 229-37.
43. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Pasty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505.
44. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005; 45: 268-71.
45. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110: 2342-8.
46. Ruzgar O, Bilge AK, Bugra Z, Umman S, Yilmaz E, Ozben B, et al. The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band. Heart Vessels 2006; 21: 309-14.
47. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88: 9267-71.
48. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435-41.